Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Pharmacol Ther. 2019 Dec 31;107(5):1200–1208. doi: 10.1002/cpt.1714

Table 4.

Adverse events reported in healthy volunteers in the test (T, +PRO) and control (C, IPERGAY) treatments.

Adverse Event C IPERGAY T +PRO
# of Subjects (% of 14 total) Severity grade # of Subjects (% of 15 total) Severity grade
Headache 2 (14) 1 4 (27) 1
Nausea 2 (14) 1 6 (40) 1
Vomiting 1 (7) 2
Loss of appetite 1 (7) 2
Nose bleed 1 (7) 1
GERD 1 (7) 2
Total AE 4 14

- Severity grade based on NCI Common Toxicity Criteria.

- Grade 1 = mild; Grade 2 = moderate